

Remo Panaccione

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4908054/publications.pdf>

Version: 2024-02-01

558
papers

42,081
citations

4658

85
h-index

2571

195
g-index

573
all docs

573
docs citations

573
times ranked

24683
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal Brain MRI of Deep Gray Matter Changes Associated With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 405-416.	1.9	11
2	Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 13-20.	1.9	14
3	Evaluation of an integrated yoga program in patients with inflammatory bowel disease: A pilot study. <i>Explore: the Journal of Science and Healing</i> , 2022, 18, 335-341.	1.0	6
4	Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study. <i>Gut</i> , 2022, 71, 1229-1231.	12.1	12
5	Association of Circulating Fibrocytes With Fibrostenotic Small Bowel Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 246-258.	1.9	10
6	Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 922-930.	1.3	8
7	P377 Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i379-i380.	1.3	1
8	P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i514-i514.	1.3	6
9	OP38 Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i044-i045.	1.3	3
10	P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i460-i460.	1.3	6
11	DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i090-i091.	1.3	7
12	Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 169-176.	0.3	5
13	OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i037-i041.	1.3	5
14	OPO8 The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 U-ACHIEVE maintenance results. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i008-i010.	1.3	5
15	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	8.1	18
16	P700 The GEM Project: Stool metabolomic profile is associated with microbiome risk score and with future onset of Crohn's disease in healthy first-degree relatives. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i596-i597.	1.3	0
17	DOP14 Validation of a new OPTical diagnosis Training platform to Improve dysplasia Characterisation in Inflammatory Bowel Disease (OPTIC-IBD): A multicentre randomised controlled study. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i063-i064.	1.3	1
18	Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. <i>Gastroenterology</i> , 2022, 162, 1876-1890.	1.3	37

#	ARTICLE	IF	CITATIONS
19	Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. <i>Gastroenterology</i> , 2022, 162, 1650-1664.e8.	1.3	88
20	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	4.4	9
21	A211 INCIDENCE OF PRIMARY SCLEROSING CHOLANGITIS: A META-ANALYSIS OF POPULATION-BASED STUDIES. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 98-99.	0.3	0
22	PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and predicting clinical outcomes and its applicability in an artificial intelligence system. <i>Gut</i> , 2022, 71, 889-898.	12.1	45
23	Review article: therapeutic targets for the pharmacologic management of coeliac disease—the future beyond a gluten-free diet. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1277-1296.	3.7	6
24	PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2022, 10, 147-159.	3.8	16
25	Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. <i>Gastroenterology</i> , 2022, 162, 1891-1910.	1.3	28
26	A73 CANADIAN INFLAMMATORY BOWEL DISEASE MOBILE APPS: CURRENT LANDSCAPE AND NEEDS. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 84-85.	0.3	0
27	Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, , .	3.7	5
28	Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1222-1234.	1.3	47
29	Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. <i>Journal of Patient-Reported Outcomes</i> , 2022, 6, 31.	1.9	21
30	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. <i>Journal of the Canadian Association of Gastroenterology</i> , 2022, 5, 208-213.	0.3	6
31	A VIRTUAL CHROMOENDOSCOPY ARTIFICIAL INTELLIGENCE SYSTEM TO DETECT ENDOSCOPIC AND HISTOLOGIC REMISSION IN ULCERATIVE COLITIS. <i>Endoscopy</i> , 2022, 54, .	1.8	0
32	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 666-678.	8.1	31
33	VALIDATION OF A NEW OPTICAL DIAGNOSIS TRAINING PLATFORM TO IMPROVE DYSPLASIA CHARACTERISATION IN INFLAMMATORY BOWEL DISEASE (OPTIC-IBD): A MULTICENTRE RANDOMISED CONTROLLED STUDY. <i>Endoscopy</i> , 2022, 54, .	1.8	0
34	Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. <i>United European Gastroenterology Journal</i> , 2022, 10, 485-495.	3.8	3
35	Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. <i>Lancet</i> , The, 2022, 399, 2113-2128.	13.7	187
36	Mediterranean-Like Dietary Pattern Associations With Gut Microbiome Composition and Subclinical Gastrointestinal Inflammation. <i>Gastroenterology</i> , 2022, 163, 685-698.	1.3	37

#	ARTICLE	IF	CITATIONS
37	Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. <i>Lancet, The</i> , 2022, 399, 2031-2046.	13.7	105
38	Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. <i>The Lancet Regional Health Americas</i> , 2022, 13, 100298.	2.6	9
39	Constrained multiple instance learning for ulcerative colitis prediction using histological images. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 224, 107012.	4.7	7
40	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1366-1376.e2.	4.4	55
41	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2064-2071.e1.	4.4	8
42	Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1096-1106.	1.9	15
43	Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2732-2743.	2.3	8
44	Smoking May Reduce the Effectiveness of Anti-TNF Therapies to Induce Clinical Response and Remission in Crohn's Disease: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 74-87.	1.3	12
45	Differential Effect of Genetic Burden on Disease Phenotypes in Crohn's Disease and Ulcerative Colitis in a Canadian Cohort. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 65-72.	0.3	2
46	Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110066.	3.2	33
47	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S10-S19.	0.3	2
48	Dietary patterns, food groups and nutrients in Crohn's disease: associations with gut and systemic inflammation. <i>Scientific Reports</i> , 2021, 11, 1674.	3.3	11
49	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S40-S45.	0.3	4
50	OUP accepted manuscript. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S1-S9.	0.3	5
51	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines' Biology, Current Evidence and Recommendations. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, S54-S60.	0.3	9
52	Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants. <i>Inflammatory Bowel Diseases</i> , 2021, , .	1.9	8
53	A123 DEFINING CROHN'S DISEASE STRICTURES USING INTESTINAL ULTRASOUND COMPARED TO HISTOPATHOLOGY. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 104-105.	0.3	0
54	Practical Deep Learning Tool For Scoring Of Ulcerative Colitis Disease Activity In Central Reading. <i>Endoscopy</i> , 2021, 53, .	1.8	0

#	ARTICLE	IF	CITATIONS
55	Drug development for ulcerative proctitis: current concepts. <i>Gut</i> , 2021, 70, 1203-1209.	12.1	7
56	An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 1558-1569.e8.	1.3	41
57	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , 2021, 160, 1452-1460.e21.	1.3	68
58	DOP41 Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S079-S080.	1.3	3
59	OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S021-S022.	1.3	17
60	P131 Serum Proteomics and Intestinal Ultrasound Differentiates Fibrostenotic and Inflammatory Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S221-S221.	1.3	0
61	P644 Hospitalization and abdominal surgery rates in CD according to drug-dispensing: a temporal trend analysis from the Brazilian public healthcare national system. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S576-S577.	1.3	1
62	OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S001-S002.	1.3	23
63	OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S026-S027.	1.3	10
64	P174 Defining Crohn's Disease Strictures Using Intestinal Ultrasound Compared to Histopathology. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S248-S248.	1.3	0
65	The Great Debate With IBD Biosimilars. <i>Crohn's & Colitis 360</i> , 2021, 3, .	1.1	1
66	Anti-Microbial Antibody Response is Associated With Future Onset of Crohn's Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. <i>Gastroenterology</i> , 2021, 161, 1540-1551.	1.3	35
67	Early Serum Infliximab Levels in Pediatric Ulcerative Colitis. <i>Frontiers in Pediatrics</i> , 2021, 9, 668978.	1.9	4
68	O4...Multicentre prospective validation study of the paddington international virtual chromoendoscopy score (PICaSSO) in ulcerative colitis. , 2021, , .		0
69	Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 1002-1014.	8.1	114
70	P031...Impact of Prior Biologic Exposure on Response to Ozanimod for Moderate-to-Severe Ulcerative Colitis in the Phase 3 True North Study. <i>American Journal of Gastroenterology</i> , 2021, 116, S8-S8.	0.4	2
71	Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110599.	3.2	16
72	Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 304-312.	4.4	129

#	ARTICLE	IF	CITATIONS
73	Anti-MADCAM therapy for ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 437-442.	3.1	9
74	Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. Advances in Therapy, 2020, 37, 364-380.	2.9	51
75	The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. Journal of the Canadian Association of Gastroenterology, 2020, 3, 234-242.	0.3	14
76	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. BMC Medical Genetics, 2020, 21, 204.	2.1	11
77	P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial. Journal of Crohn's and Colitis, 2020, 14, S562-S562.	1.3	0
78	Harnessing localised delivery of gut-selective therapy for ulcerative colitis. The Lancet Gastroenterology and Hepatology, 2020, 5, 1031-1032.	8.1	1
79	P341 Induction of response and remission: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S327-S328.	1.3	0
80	P354 Objectively measured time spent sitting, standing upright, and stepping is associated with disease severity and faecal calprotectin in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S337-S337.	1.3	1
81	P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S410-S411.	1.3	0
82	Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease. Gastroenterology, 2020, 159, 2092-2100.e5.	1.3	156
83	Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 568-569.	3.7	0
84	Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force. Journal of Crohn's and Colitis, 2020, 14, S785-S790.	1.3	12
85	Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1353-1365.	3.7	97
86	Systematic review: medical therapy for fibrostenosing Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 1233-1246.	3.7	26
87	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut, 2020, 69, 658-664.	12.1	21
88	Human interleukin-4-treated regulatory macrophages promote epithelial wound healing and reduce colitis in a mouse model. Science Advances, 2020, 6, eaba4376.	10.3	46
89	Assessment of Endoscopic Healing by Using Advanced Technologies Reflects Histological Healing in Ulcerative Colitis. Journal of Crohn's and Colitis, 2020, 14, 1282-1289.	1.3	19
90	P448 Dose adjustment in patients with moderate-to-severe ulcerative colitis: results from the UNIFI maintenance study long-term extension. Journal of Crohn's and Colitis, 2020, 14, S403-S403.	1.3	2

#	ARTICLE	IF	CITATIONS
91	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 139-147.	1.3	126
92	Crohn's disease. <i>Nature Reviews Disease Primers</i> , 2020, 6, 22.	30.5	420
93	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	1.9	27
94	Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 254-266.	1.3	175
95	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2526-2534.e9.	4.4	45
96	Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. <i>PLoS ONE</i> , 2020, 15, e0227635.	2.5	20
97	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	4.4	27
98	A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn's Disease in Remission. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1547-1557.	1.3	43
99	OP01 Higher vs. standard adalimumab maintenance regimens in patients with moderately to severely active ulcerative colitis: Results from the SERENE-UC maintenance study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S001-S001.	1.3	17
100	OP26 The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S023-S024.	1.3	4
101	Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1031-1038.	3.7	80
102	Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 598-606.	8.1	79
103	P068 MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. <i>Inflammatory Bowel Diseases</i> , 2020, 26, S10-S11.	1.9	0
104	Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1658-1675.	3.7	40
105	Editorial: is age just a number when it comes to treatment of inflammatory bowel disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1615-1616.	3.7	1
106	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	1.9	73
107	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	4.4	32
108	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.3	32

#	ARTICLE	IF	CITATIONS
109	P104 THE INCIDENCE OF INFLAMMATORY BOWEL DISEASE: ANALYZING HISTORICAL TRENDS TO PREDICT THE FUTURE. <i>Gastroenterology</i> , 2019, 156, S72.	1.3	0
110	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. <i>Frontiers in Medicine</i> , 2019, 6, 170.	2.6	6
111	P435 Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S326-S327.	1.3	1
112	P466 Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S344-S344.	1.3	6
113	07 A SIGNIFICANT DECLINE IN COLECTOMY RATES FOR COLORECTAL CANCER IN PATIENTS WITH ULCERATIVE COLITIS. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S43-S44.	1.9	0
114	The Role of Bowel Ultrasound in Detecting Subclinical Inflammation in Pregnant Women with Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 153-160.	0.3	15
115	P023 PATIENT AND HEALTHCARE PROFESSIONAL VIEWS ON EMOTIONAL HEALTH AND INTIMACY IN ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S12-S12.	1.9	0
116	Improving the quality of surveillance colonoscopy in inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 971-983.	8.1	28
117	Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report. <i>BMC Gastroenterology</i> , 2019, 19, 162.	2.0	38
118	Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019, 381, 1201-1214.	27.0	703
119	OP26 Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S018-S020.	1.3	8
120	OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S024-S025.	1.3	12
121	Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1142-1149.	2.3	5
122	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 5-23.	3.7	66
123	P099 HOSPITALIZATIONS FOR IBD THROUGHOUT THE WORLD: A SYSTEMATIC REVIEW WITH TEMPORAL ANALYSES. <i>Gastroenterology</i> , 2019, 156, S68-S69.	1.3	0
124	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <i>Colorectal Disease</i> , 2019, 21, 1279-1287.	1.4	12
125	Nutrition Center of Excellence (COE) in Inflammatory Bowel Disease—A Model and Rationale for Development. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 63-70.	0.3	1
126	P023 PATIENT AND HEALTHCARE PROFESSIONAL VIEWS ON EMOTIONAL HEALTH AND INTIMACY IN ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Gastroenterology</i> , 2019, 156, S17.	1.3	0

#	ARTICLE	IF	CITATIONS
127	Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. <i>Advances in Therapy</i> , 2019, 36, 1672-1683.	2.9	34
128	P024 PATIENT AND HEALTHCARE PROVIDER VIEWS ON ULCERATIVE COLITIS TREATMENT GOALS AND QUALITY OF LIFE: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Gastroenterology</i> , 2019, 156, S17-S18.	1.3	1
129	07 A SIGNIFICANT DECLINE IN COLECTOMY RATES FOR COLORECTAL CANCER IN PATIENTS WITH ULCERATIVE COLITIS. <i>Gastroenterology</i> , 2019, 156, S63.	1.3	1
130	P006 DISCORDANCE OF COMMUNICATION PRIORITIES BETWEEN HEALTHCARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Gastroenterology</i> , 2019, 156, S6-S7.	1.3	1
131	P005 DELAY IN DIAGNOSIS OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Gastroenterology</i> , 2019, 156, S6.	1.3	2
132	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. <i>Gastroenterology</i> , 2019, 156, 1345-1353.e4.	1.3	273
133	P472 Efficacy of intravenous ustekinumab re-induction in patients with Crohn's disease with a loss of response. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S347-S348.	1.3	4
134	Ulcerative Colitis: Shifting Sands. <i>Drugs in R and D</i> , 2019, 19, 227-234.	2.2	13
135	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 287-295.	8.1	44
136	P603 Paediatric onset inflammatory bowel disease is not associated with more disability compared with adult onset disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S417-S418.	1.3	0
137	P712 Tofacitinib efficacy in patients with moderate to severe ulcerative colitis: Subgroup analyses of OCTAVE Induction 1 and 2 and OCTAVE Sustain by 5-aminosalicylates use. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S477-S477.	1.3	2
138	P717 The use of combination biologic therapy in inflammatory bowel disease: A single tertiary-centre experience. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S480-S480.	1.3	3
139	P006 DISCORDANCE OF COMMUNICATION PRIORITIES BETWEEN HEALTHCARE PROFESSIONALS AND PATIENTS WITH ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S4-S5.	1.9	0
140	P164 Mucosal healing (MH) assessed with PICaSSO (Paddington International Virtual) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 232 Td (Ch) histological normalisation using the ECAP (Extent Chronicity Activity Plus) score. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S170-S171.	1.3	0
141	P739 The progression of inflammatory bowel disease throughout Latin America: a systematic review. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S490-S491.	1.3	0
142	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 38-39, 101604.	2.4	28
143	P105 THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE THROUGHOUT LATIN AMERICA: A SYSTEMATIC REVIEW. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S51-S51.	1.9	2
144	Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2374-2376.e2.	4.4	15

#	ARTICLE	IF	CITATIONS
145	P105 THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE THROUGHOUT LATIN AMERICA: A SYSTEMATIC REVIEW. <i>Gastroenterology</i> , 2019, 156, S72-S73.	1.3	1
146	P005 DELAY IN DIAGNOSIS OF ULCERATIVE COLITIS: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S4-S4.	1.9	0
147	P099 HOSPITALIZATIONS FOR IBD THROUGHOUT THE WORLD: A SYSTEMATIC REVIEW WITH TEMPORAL ANALYSES. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S47-S48.	1.9	2
148	P104 THE INCIDENCE OF INFLAMMATORY BOWEL DISEASE: ANALYZING HISTORICAL TRENDS TO PREDICT THE FUTURE. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S50-S51.	1.9	1
149	Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 725-734.	1.3	25
150	Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1522-1531.	1.9	16
151	715 Corticosteroid Sparing Effects of Ustekinumab Therapy in UC Patients: Results From the UNIFI Program. <i>American Journal of Gastroenterology</i> , 2019, 114, S421-S421.	0.4	0
152	PTH-077...De-escalating therapy in patients with crohn's disease receiving adalimumab: subgroup analysis of the calm study. , 2019, , .		0
153	842 Impact of Response and Inflammatory Burden at Start of Maintenance Therapy on Clinical Efficacy of Ustekinumab Dosing Regimen in UC: Week 44 Results From UNIFI. <i>American Journal of Gastroenterology</i> , 2019, 114, S487-S488.	0.4	0
154	P024 PATIENT AND HEALTHCARE PROVIDER VIEWS ON ULCERATIVE COLITIS TREATMENT GOALS AND QUALITY OF LIFE: RESULTS OF A GLOBAL ULCERATIVE COLITIS NARRATIVE SURVEY. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S12-S12.	1.9	0
155	P580 Improvement in disease activity is associated with less disability in a prospective study of paediatric transition patients with IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S404-S405.	1.3	0
156	The Clinical Implications of Nocebo Effects for Biosimilar Therapy. <i>Frontiers in Pharmacology</i> , 2019, 10, 1372.	3.5	59
157	P296 Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S247-S248.	1.3	3
158	678 Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE. <i>American Journal of Gastroenterology</i> , 2019, 114, S399-S399.	0.4	0
159	Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 139-147.	4.4	138
160	An Unusual Cause of Esophageal Obstruction and Hematemesis. <i>Gastroenterology</i> , 2019, 156, 29-30.	1.3	2
161	Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1673-1679.e1.	4.4	26
162	Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 172-181.	1.3	27

#	ARTICLE	IF	CITATIONS
163	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). <i>Gut</i> , 2019, 68, 40-48.	12.1	132
164	Efficacy and Safety of Ustekinumab as Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UNIFI. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	3
165	836 Tofacitinib Efficacy in Patients With Moderate to Severe Ulcerative Colitis: Subgroup Analyses of OCTAVE Induction 1 & 2 and OCTAVE Sustain by 5-Aminosalicylates Use. <i>American Journal of Gastroenterology</i> , 2019, 114, S483-S484.	0.4	2
166	Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?. <i>Current Drug Targets</i> , 2019, 20, 1369-1372.	2.1	5
167	Clinical disease activity in the CALM study – Authors' reply. <i>Lancet, The</i> , 2018, 391, 1482.	13.7	2
168	Modern management of perianal fistulas in Crohn's disease: future directions. <i>Gut</i> , 2018, 67, 1181-1194.	12.1	114
169	Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 930-938.	1.3	20
170	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31
171	Real-time Interobserver Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease: An International Multicenter Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2001-2006.	1.9	39
172	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1407-1419.e22.	4.4	41
173	FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects. <i>Gut Microbes</i> , 2018, 9, 1-12.	9.8	33
174	Pregnant Women with Inflammatory Bowel Disease Are at Increased Risk of Vitamin D Insufficiency: A Cross-Sectional Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 702-709.	1.3	14
175	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	12.1	108
176	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 637-647.e13.	4.4	44
177	Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 219-228.	3.7	35
178	A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. <i>American Journal of Gastroenterology</i> , 2018, 113, 225-234.	0.4	106
179	P634 Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S430-S431.	1.3	2
180	OP0233...Long-term safety of adalimumab in adult patients from global clinical trials across multiple indications: an updated analysis in 29,987 patients representing 56,951 patient-years. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
181	Cross-Sectional Analysis of Overall Dietary Intake and Mediterranean Dietary Pattern in Patients with Crohn's Disease. <i>Nutrients</i> , 2018, 10, 1761.	4.1	61
182	Patterns and predictors of long-term retention of inflammatory bowel or rheumatoid disease patients on innovator infliximab: an analysis of a Canadian prescriptions claims database. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 1805-1814.	1.8	3
183	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.3	10
184	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 115-123.	0.3	34
185	Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878361.	3.2	11
186	Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 626-637.	3.7	43
187	Fistula-associated anal carcinoma in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 917-925.	3.0	20
188	Clinical utility of ustekinumab in Crohn's disease. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 35-47.	3.5	32
189	The old versus the new: which do you keep in postoperative Crohn's disease?. <i>Intestinal Research</i> , 2018, 16, 319.	2.6	2
190	Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-up in the PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2018, 113, 872-882.	0.4	58
191	Customized Use of Anti-Tumour Necrosis Factor- α Therapy During Pregnancy. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1379-1380.	1.3	0
192	Characterization of Creatine Kinase Levels in the Tofacitinib Ulcerative Colitis Development Program. <i>American Journal of Gastroenterology</i> , 2018, 113, S352-S353.	0.4	0
193	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw176.	1.3	141
194	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw177.	1.3	140
195	Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1584-1592.	0.4	37
196	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	12.1	630
197	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017, 66, 1049-1059.	12.1	274
198	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically refractory Crohn's disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1232-1243.	3.7	141

#	ARTICLE	IF	CITATIONS
199	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 461-472.	1.9	52
200	Adalimumab for the Treatment of Crohn's Disease. , 2017, , 343-349.		0
201	The Incidence of Cardiovascular Events in Patients with Crohn's Disease Treated with Vedolizumab and Anti-TNF Therapies. <i>Gastroenterology</i> , 2017, 152, S577-S578.	1.3	4
202	Long-Term Safety of Adalimumab in Patients with Crohn's Disease: Final Data from Pyramid Registry. <i>Gastroenterology</i> , 2017, 152, S137.	1.3	1
203	Point of Care Ultrasound Accurately Distinguishes Inflammatory from Non Inflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. <i>Gastroenterology</i> , 2017, 152, S644-S645.	1.3	0
204	Pregnant Women with Inflammatory Bowel Disease (IBD) are at Significantly Increased Risk of Vitamin D Insufficiency. <i>Gastroenterology</i> , 2017, 152, S370.	1.3	0
205	Effect of Adalimumab dose Escalation on Clinical, Health-Related Quality of Life, Treatment Satisfaction and Work Productivity Outcomes Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada. <i>Gastroenterology</i> , 2017, 152, S742-S743.	1.3	0
206	Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm. <i>Gastroenterology</i> , 2017, 152, S155.	1.3	16
207	Crossover Subsets of CD4+ T Lymphocytes in the Intestinal Lamina Propria of Patients with Crohn's Disease and Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2357-2368.	2.3	25
208	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , 2017, 7, e016146.	1.9	35
209	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 833-839.	1.9	94
210	Asthma Is Associated With Subsequent Development of Inflammatory Bowel Disease: A Population-based Case-Control Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1405-1412.e3.	4.4	34
211	Beyond white light: optical enhancement in conjunction with magnification colonoscopy for the assessment of mucosal healing in ulcerative colitis. <i>Endoscopy</i> , 2017, 49, 553-559.	1.8	39
212	The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1329-1338.	3.7	71
213	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	13.7	633
214	Evolving Trends in the Epidemiology of IBD in the 21st Century: A Systematic Review of Population-Based Studies. <i>American Journal of Gastroenterology</i> , 2017, 112, S319-S320.	0.4	8
215	Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. <i>Lancet, The</i> , 2017, 390, 2769-2778.	13.7	3,705
216	PTH-027...Location and kudo pit pattern reflect neoplastic histology of lesions detected at surveillance colonoscopy in inflammatory bowel disease. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
217	P.11.8: Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , 2017, 49, e205.	0.9	0
218	Ustekinumab is Effective for Inducing Clinical, Endoscopic, and Radiographic Response and Remission in Refractory Moderate-to-Severe Crohn's Disease: A Multicentre Cohort Study. <i>Gastroenterology</i> , 2017, 152, S410-S411.	1.3	1
219	Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 463-464.	3.7	1
220	Dietary Intake of Patients with Crohn's Disease in Remission: A Single Center Experience. <i>Gastroenterology</i> , 2017, 152, S1015.	1.3	0
221	Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1317-1325.	1.3	35
222	The Simple Pediatric Activity Ultrasound Score (SPAUSS) for the Accurate Detection of Pediatric Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S80.	1.3	0
223	Combining Patient Preferences and Comparative Effectiveness Research to Inform Treatment Approaches for Maintenance Therapy in Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S591-S592.	1.3	0
224	Effect of Adalimumab on Extraintestinal Manifestations Among Patients with Ulcerative Colitis in a Clinical Practice Setting: Results from Inspirada. <i>Gastroenterology</i> , 2017, 152, S743.	1.3	0
225	Adalimumab Long-Term Effectiveness in Adalimumab-Naïve Patients with Crohn's Disease: Final Data from Pyramid Registry. <i>Gastroenterology</i> , 2017, 152, S743.	1.3	0
226	The NOD2 -Smoking Interaction in Crohn's Disease is likely Specific to the 1007 fs Mutation and may be Explained by Age at Diagnosis: A Meta-Analysis and Case-Only Study. <i>EBioMedicine</i> , 2017, 21, 188-196.	6.1	20
227	Preoperative Ustekinumab Treatment is not Associated with Increased Postoperative Complications in Crohn's Disease: A Canadian Multicentre Case-Control Cohort Study. <i>Gastroenterology</i> , 2017, 152, S577.	1.3	16
228	A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by Qbeco in Subjects with Moderate to Severe Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S600.	1.3	1
229	Long-Term Effectiveness and Safety of Vedolizumab in Patients with Ulcerative Colitis: 5-Year Cumulative Exposure of Gemini 1 Completers Rolling into the Gemini Open-Label Extension Study. <i>Gastroenterology</i> , 2017, 152, S602.	1.3	7
230	Location and Kudo Pit Pattern Reflect Neoplastic Histology of Lesions Detected at Surveillance Colonoscopy in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S642.	1.3	0
231	Adalimumab Efficacy and Safety by Disease Duration: Analysis of Pooled Studies of Crohn's Disease. <i>Gastroenterology</i> , 2017, 152, S744.	1.3	2
232	Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1272-1277.	1.9	17
233	Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, E26-E37.	1.9	11
234	Patients with Ulcerative Colitis Taking Asacol have 1000-Fold Higher Levels of Dibutyl Phthalate as Compared to Mezavant or Salofalk. <i>Gastroenterology</i> , 2017, 152, S408.	1.3	0

#	ARTICLE	IF	CITATIONS
235	The 5C Concept and 5S Principles in Inflammatory Bowel Disease Management. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1302-1308.	1.3	12
236	A Simple Ultrasound Score for the Accurate Detection of Inflammatory Activity in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2001-2010.	1.9	61
237	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 1840-1848.	0.4	140
238	OP0076...Risk of developing additional immune mediated manifestations for patients with systemic arthritides. , 2017, , .		0
239	Adalimumab Long-term Effectiveness in Adalimumab-Naive Patients With Crohn's Disease: Final Data From PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2017, 112, S363-S364.	0.4	1
240	PYRAMID Registry: Long-term Safety of Adalimumab by Age in Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S396-S397.	0.4	0
241	Prevalence and Anatomic Distribution of Serrated and Adenomatous Lesions in Patients with Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2017, 2017, 1-8.	1.9	43
242	P381 Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S271-S271.	1.3	0
243	PYRAMID Registry: Long-term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S384.	0.4	1
244	Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. <i>Intestinal Research</i> , 2017, 15, 160.	2.6	11
245	Paradoxical Trends in Hospitalization Rates for the Inflammatory Bowel Diseases Between the Western World and Newly Industrialized Countries: A Study of the Organization for Economic Cooperation and Development (OECD). <i>American Journal of Gastroenterology</i> , 2017, 112, S321-S323.	0.4	0
246	A Treat to Target Approach Decreases the Rate of CD-Related Adverse Outcomes versus a Clinical Approach in Patients With Moderate to Severely Active Crohn's Disease: Data From CALM 2017 ACG Governors Award for Excellence in Clinical Research. <i>American Journal of Gastroenterology</i> , 2017, 112, S321.	0.4	1
247	Symptomatic Improvement Within 3 Days With Tofacitinib Induction Therapy in Patients With Ulcerative Colitis: Results From OCTAVE Induction 1 and 2. <i>American Journal of Gastroenterology</i> , 2017, 112, S331.	0.4	0
248	Point of Care Ultrasound Accurately Distinguishes Inflammatory from Noninflammatory Disease in Patients Presenting with Abdominal Pain and Diarrhea. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7.	1.9	23
249	Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 638-647.	1.9	80
250	The Association of Smoking and Surgery in Inflammatory Bowel Disease is Modified by Age at Diagnosis. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e165.	2.5	15
251	Smoking influences the need for surgery in patients with the inflammatory bowel diseases: a systematic review and meta-analysis incorporating disease duration. <i>BMC Gastroenterology</i> , 2016, 16, 143.	2.0	45
252	Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1779-1792.	1.9	73

#	ARTICLE	IF	CITATIONS
253	PTH-072â€¦Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab: Abstract PTH-072 Table 1. Gut, 2016, 65, A254.2-A255.	12.1	0
254	1076 A Simple, Validated Ultrasonographic Score for the Detection of Inflammation in Established Crohn's Disease. Gastroenterology, 2016, 150, S213.	1.3	0
255	Mo1832 Validation of Administrative Data for Capturing Crohn's Disease Patients Requiring Surgical Bowel Resection. Gastroenterology, 2016, 150, S788.	1.3	1
256	76 Surgical Resection Rates for Crohn's Disease Are Decreasing: A Population-Based Time Trend Analysis. Gastroenterology, 2016, 150, S20.	1.3	1
257	Su1012 Canadian Patient and Caregiver Perspectives on Subsequent Entry Biologics/Biosimilars for Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S443-S444.	1.3	7
258	Mo1090 The Costs of Care for Patients With Ulcerative Colitis: Effect of Adalimumab on Health Care Resources Utilisation in Clinical Practice From INSPIRADA. Gastroenterology, 2016, 150, S631.	1.3	0
259	812f Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals With Inflammatory Bowel Disease. Gastroenterology, 2016, 150, S1268.	1.3	3
260	Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. American Journal of Gastroenterology, 2016, 111, 691-704.	0.4	56
261	Recent advances in the endoscopic assessment of ulcerative colitis. Techniques in Gastrointestinal Endoscopy, 2016, 18, 116-122.	0.3	1
262	Association of host genome with intestinal microbial composition in a large healthy cohort. Nature Genetics, 2016, 48, 1413-1417.	21.4	388
263	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 1599-1607.	0.4	300
264	The Crohn's Diseaseâ€”Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clinical Gastroenterology and Hepatology, 2016, 14, e121-e122.	4.4	3
265	PWE-020â€¦Corticosteroid Dose Reduction with Vedolizumab Treatment of Crohn's Disease: Abstract PWE-020 Table 1. Gut, 2016, 65, A147.1-A147.	12.1	0
266	Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1596-1608.	1.9	28
267	Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2711-2723.	1.9	14
268	624 Final Results of a Randomized Study Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. Gastroenterology, 2016, 150, S129.	1.3	10
269	856 Efficacy and Safety of Oral Tofacitinib for Maintenance Therapy in Patients With Moderate to Severe Crohn's Disease: Results of a Phase 2B Randomized Placebo-Controlled Trial. Gastroenterology, 2016, 150, S183.	1.3	7
270	Tu1914 PYRAMID Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year 7. Gastroenterology, 2016, 150, S976.	1.3	0

#	ARTICLE	IF	CITATIONS
271	Sa1105 Delayed Timing of Post-Operative Colonoscopy Within 1 Year Does Not Predict a More Severe Rutgeerts Score. <i>Gastroenterology</i> , 2016, 150, S241-S242.	1.3	0
272	Tu1919 Phthalate Levels are Higher in Patients With Ulcerative Colitis Taking Asacol as Compared to Mezavant: A Comparative Safety Analysis. <i>Gastroenterology</i> , 2016, 150, S977-S978.	1.3	0
273	1074 The Concordance Between Disease Activity and Prevalence of Th1 Subsets in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 150, S212-S213.	1.3	0
274	513 Pregnancy Alters the Pharmacokinetics of Infliximab and Adalimumab in IBD Women. <i>Gastroenterology</i> , 2016, 150, S105.	1.3	6
275	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. <i>Gastroenterology</i> , 2016, 150, S155.	1.3	6
276	Sa2028 Inter-Observer Agreement in Bowel Ultrasonography for Diagnostic Assessment in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, S433-S434.	1.3	0
277	Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel. <i>Gastroenterology</i> , 2016, 150, S991.	1.3	0
278	The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 330-338.	3.2	15
279	Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1168-1183.	1.9	137
280	Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1385-1394.	1.3	115
281	Vedolizumab for the treatment of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 129-135.	3.1	1
282	Targeted Biopsies Identify Larger Proportions of Patients With Colonic Neoplasia Undergoing High-Definition Colonoscopy, Dye Chromoendoscopy, or Electronic Virtual Chromoendoscopy. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 704-712.e4.	4.4	65
283	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016, 150, 1568-1578.	1.3	251
284	Smoking Is Associated with an Increased Risk for Surgery in Diverticulitis: A Case Control Study. <i>PLoS ONE</i> , 2016, 11, e0153871.	2.5	9
285	Ustekinumab Is Effective for the Induction and Maintenance of Response in Crohn's Disease: A Multi-center Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, S294.	0.4	1
286	Type I interferons for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2015, , CD006790.	2.8	19
287	Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated With Vedolizumab During the GEMINI 1 Trial. <i>American Journal of Gastroenterology</i> , 2015, 110, S790.	0.4	3
288	Briakinumab for Treatment of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	67

#	ARTICLE	IF	CITATIONS
289	The Rising Burden of Inflammatory Bowel Disease in North America from 2015 to 2025: A Predictive Model. <i>American Journal of Gastroenterology</i> , 2015, 110, S829.	0.4	10
290	Cliniciansâ€™ Guide to the Use of Fecal Calprotectin to Identify and Monitor Disease Activity in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 369-372.	1.9	58
291	Living with Inflammatory Bowel Disease: A Crohnâ€™s and Colitis Canada Survey. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 77-84.	1.9	56
292	Ulcerative Colitis-Associated Hospitalization Costs: A Population-Based Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 357-362.	1.9	19
293	Transperineal Ultrasonography in Perianal Crohn Disease: A Valuable Imaging Modality. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 445-447.	1.9	17
294	Biomarkers as Potential Treatment Targets in Inflammatory Bowel Disease: A Systematic Review. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 203-208.	1.9	20
295	Clinical predictors of thiopurine-related adverse events in Crohn's disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 7795.	3.3	28
296	Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. <i>Gastroenterology</i> , 2015, 149, 928-937.	1.3	97
297	Intrapartum Corticosteroid use Significantly Increases the Risk of Gestational Diabetes in Women with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 223-230.	1.3	41
298	Clinic-based Point of Care Transabdominal Ultrasound for Monitoring Crohnâ€™s Disease: Impact on Clinical Decision Making. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 795-801.	1.3	69
299	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. <i>Gastroenterology</i> , 2015, 148, 344-354.e5.	1.3	226
300	Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus. <i>Gastroenterology</i> , 2015, 148, 1035-1058.e3.	1.3	323
301	Funding a Smoking Cessation Program for Crohnâ€™s Disease: An Economic Evaluation. <i>American Journal of Gastroenterology</i> , 2015, 110, 368-377.	0.4	25
302	Sa1754 Distinctive Th17 Lymphocyte Plasticity in Intestinal Lamina Propria of IBD Patients Compared With Healthy Controls. <i>Gastroenterology</i> , 2015, 148, S-323.	1.3	4
303	327 A Randomized Comparison of High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy Using iSCAN for Detection of Colonic Dysplastic Lesions During IBD Surveillance Colonoscopy. <i>Gastroenterology</i> , 2015, 148, S-73-S-74.	1.3	6
304	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 928-935.e2.	4.4	181
305	Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel high definition colonoscopy and refined histological gradings. <i>Endoscopy</i> , 2015, 47, 726-734.	1.8	53
306	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015, 110, 1324-1338.	0.4	1,425

#	ARTICLE	IF	CITATIONS
307	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 1825-1834.	13.7	354
308	Corticosteroid Dose Reduction With Vedolizumab Treatment of Crohn's Disease During the GEMINI 2 Trial. <i>American Journal of Gastroenterology</i> , 2015, 110, S789.	0.4	1
309	Colectomy is a risk factor for venous thromboembolism in ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2015, 21, 1251.	3.3	37
310	The Interaction Between NOD2 and Smoking Is Specific to the 1007fs SNP of the NOD2 Gene in Crohn's Disease: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2015, 110, S838.	0.4	0
311	Long-Term Safety of Adalimumab in Clinical Trials in Adult Patients With Crohn's Disease or Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2015, 110, S789-S790.	0.4	0
312	Age at Diagnosis of Crohn's Disease May Explain NOD2-Smoking Interactions. <i>American Journal of Gastroenterology</i> , 2015, 110, S837.	0.4	1
313	Long-Term Efficacy of Vedolizumab Therapy for Patients With Ulcerative Colitis: Presidential Poster. <i>American Journal of Gastroenterology</i> , 2014, 109, S477-S478.	0.4	3
314	Deep Remission With Vedolizumab in Patients With Ulcerative Colitis: Evaluating Various Combinations of Endoscopic and Patient-Reported Outcomes. <i>American Journal of Gastroenterology</i> , 2014, 109, S483.	0.4	0
315	Canadian Association of Gastroenterology Position Statement Regarding the Use of Thiopurines for the Treatment of Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 371-372.	1.9	10
316	<i>Clostridium difficile</i> Infection Worsens the Prognosis of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 373-380.	1.9	21
317	Serrated Adenoma Prevalence in Inflammatory Bowel Disease Surveillance Colonoscopy, And Characteristics Revealed by Chromoendoscopy and Virtual Chromoendoscopy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 589-594.	1.9	25
318	Management of the Pregnant Inflammatory Bowel Disease Patient on Antitumour Necrosis Factor Therapy: State of the Art and Future Directions. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 505-509.	1.9	6
319	Cumulative Incidence of Second Intestinal Resection in Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Studies. <i>American Journal of Gastroenterology</i> , 2014, 109, 1739-1748.	0.4	178
320	Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2046-2055.	1.9	8
321	Opposing Effects of Smoking in Ulcerative Colitis and Crohn's Disease May Be Explained by Differential Effects on Dendritic Cells. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 800-810.	1.9	33
322	Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 472-480.	1.9	169
323	Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, 681-688.e1.	1.3	294
324	P150 Responsiveness of endoscopic indices in the evaluation of ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S124.	1.3	6

#	ARTICLE	IF	CITATIONS
325	Corrigendum to "Optimising monitoring in the management of Crohn's disease: A physician perspective" [Journal of Crohn's and Colitis volume 7 (2013) 653-669]. Journal of Crohn's and Colitis, 2014, 8, 441.	1.3	0
326	Novel concepts in inflammatory bowel disease. British Medical Bulletin, 2014, 109, 55-72.	6.9	4
327	Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3. American Journal of Gastroenterology, 2014, 109, 1771-1780.	0.4	140
328	Update on Ustekinumab for the Treatment of Crohn's Disease. Gastroenterology Clinics of North America, 2014, 43, 619-630.	2.2	8
329	Phenotypic Features of Crohn's Disease Associated With Failure of Medical Treatment. Clinical Gastroenterology and Hepatology, 2014, 12, 434-442.e1.	4.4	56
330	Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. Journal of Crohn's and Colitis, 2014, 8, 927-935.	1.3	117
331	P571 Adalimumab maintains remission for up to 4 years in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, S306.	1.3	0
332	Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis. Gastroenterology, 2014, 146, 392-400.e3.	1.3	778
333	P364 Resected fibrostenotic intestine from Crohn's disease patients express significant TNF in proliferative fibroblasts and in extracellular matrix. Journal of Crohn's and Colitis, 2014, 8, S217.	1.3	0
334	P256 Complete mucosal healing defined by endoscopic Mayo subscore still demonstrates abnormalities by novel iSCAN endoscopic and refined histological gradings. Journal of Crohn's and Colitis, 2014, 8, S170.	1.3	0
335	Will Cross-Sectional Imaging Replace Endoscopy for Monitoring Response to Therapy in Crohn's Disease?. Gastroenterology, 2014, 146, 334-336.	1.3	6
336	OP004 Early combined immunosuppression for the management of Crohn's disease: A community-based cluster randomized trial. Journal of Crohn's and Colitis, 2014, 8, S2-S3.	1.3	15
337	Postoperative Mortality for the Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies: ACG Fellow Award. American Journal of Gastroenterology, 2014, 109, S639.	0.4	0
338	C-Reactive Protein and Erythrocyte Sedimentation Rate Do Not Correlate With Disease Activity in Pregnant Women With IBD. American Journal of Gastroenterology, 2014, 109, S516-S517.	0.4	0
339	Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions. Inflammatory Bowel Diseases, 2013, 19, 445-456.	1.9	50
340	Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis, 2013, 7, 653-669.	1.3	96
341	Tu1106 Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis. Gastroenterology, 2013, 144, S-763.	1.3	3
342	Mo1297 Mode of Delivery in Inflammatory Bowel Disease Patients: A Population-Based Study. Gastroenterology, 2013, 144, S-629.	1.3	1

#	ARTICLE	IF	CITATIONS
343	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 149-157.e2.	1.3	196
344	Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies. <i>Gastroenterology</i> , 2013, 145, 996-1006.	1.3	670
345	P163 Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM/ADHERE. <i>Journal of Crohn's and Colitis</i> , 2013, 7, S74.	1.3	1
346	Commentary: detection of infliximab levels and anti-infliximab antibodies. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 153-154.	3.7	2
347	Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 517-524.	0.9	484
348	Nationwide Temporal Trends in Incidence of Hospitalization and Surgical Intestinal Resection in Pediatric Inflammatory Bowel Diseases in the United States from 1997 to 2009. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2423-2432.	1.9	49
349	Increased Prevalence of Circulating Novel IL-17 Secreting Foxp3 Expressing CD4+ T Cells and Defective Suppressive Function of Circulating Foxp3+ Regulatory Cells Support Plasticity Between Th17 and Regulatory T Cells in Inflammatory Bowel Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2522-2534.	1.9	162
350	Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1002-1024.	3.7	63
351	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 447-459.	3.7	96
352	Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1236-1247.	3.7	97
353	52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1700-1709.	1.9	75
354	Advances in Novel Diagnostic Endoscopic Imaging Techniques in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 873-880.	1.9	20
355	Evolving Definitions of Remission in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1645-1653.	1.9	49
356	The Increasing Weight of Crohn's Disease Subjects in Clinical Trials. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2949-2956.	1.9	78
357	SAT0130...Long-term safety of adalimumab in patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, and crohn's disease. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 514.3-515.	0.9	10
358	Environment and the Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2013, 27, e18-e24.	1.7	121
359	Cumulative Incidence of Second Major Abdominal Surgery Crohn's Disease: A Systematic Review and Meta-analysis of Population-based Studies. <i>American Journal of Gastroenterology</i> , 2013, 108, S525-S526.	0.4	0
360	Long-term Safety of Vedolizumab for the Treatment of Ulcerative Colitis or Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2013, 108, S502-S503.	0.4	16

#	ARTICLE	IF	CITATIONS
361	Proteinase 3 (PR3) Autoantibodies as a Serological Marker in Inflammatory Bowel Disease (IBD). American Journal of Gastroenterology, 2013, 108, S523.	0.4	2
362	Indications for Elective Caesarean Section in IBD: A Population-based Study. American Journal of Gastroenterology, 2013, 108, S524-S525.	0.4	1
363	Induction Treatment with Anti-TNF Decreases C-Reactive Protein Levels among Crohn's Disease Patients: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2013, 108, S540.	0.4	0
364	Response Rates in the Control Arms of Randomized Controlled Trials: A Systematic Review and Meta-analysis of Trials on Monoclonal Antibodies in Ulcerative Colitis. American Journal of Gastroenterology, 2013, 108, S558.	0.4	0
365	Colorectal Neoplasia Surveillance in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: An Economic Evaluation. American Journal of Gastroenterology, 2013, 108, S637.	0.4	0
366	Long-term Effectiveness of Adalimumab in Crohn's Disease: Observational Data from the PYRAMID Registry. American Journal of Gastroenterology, 2013, 108, S543-S544.	0.4	0
367	Pyramid Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year Five. American Journal of Gastroenterology, 2013, 108, S506.	0.4	0
368	A Cost-Utility Analysis of Smoking Cessation Programs for Patients with Crohn's Disease. American Journal of Gastroenterology, 2013, 108, S525.	0.4	0
369	Hospitalization Rates in Patients with Crohn's Disease and Deep Remission: Data from the 56-week CHARM Trial. American Journal of Gastroenterology, 2013, 108, S547.	0.4	0
370	The Comparative Efficacy of Remission Maintenance Therapy in Crohn's Disease: A Bayesian Network Meta-analysis. American Journal of Gastroenterology, 2013, 108, S535-S536.	0.4	0
371	Mechanisms of inflammatory bowel disease. Gastroenterology and Hepatology, 2013, 9, 529-32.	0.1	2
372	TOUCHÂ® Patient Reported Outcomes Study: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients. Inflammatory Bowel Diseases, 2012, 18, S41-S42.	1.9	0
373	Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2012, 18, S20-S21.	1.9	2
374	TOUCHÂ® Patient Reported Outcomes Study: The Impact of Natalizumab on Crohn's Disease Severity. Inflammatory Bowel Diseases, 2012, 18, S41.	1.9	0
375	PWE-260â€¦Optimal C reactive protein cut-off point for predicting hospitalisation in patients with moderately active Crohn's disease. Gut, 2012, 61, A403.3-A404.	12.1	0
376	TOUCHÂ® PRO Study: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction. Inflammatory Bowel Diseases, 2012, 18, S42.	1.9	0
377	Adalimumab Sustains Deep Remission for 3 Years: Data From CHARM and ADHERE. Inflammatory Bowel Diseases, 2012, 18, S39.	1.9	1
378	Tu1272 Cumulative Incidence of First Intestinal Surgery in Adult and Pediatric Crohn's Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2012, 142, S-790.	1.3	2

#	ARTICLE	IF	CITATIONS
379	Quantitative Metabolomic Profiling of Serum, Plasma, and Urine by ¹ H NMR Spectroscopy Discriminates between Patients with Inflammatory Bowel Disease and Healthy Individuals. <i>Journal of Proteome Research</i> , 2012, 11, 3344-3357.	3.7	200
380	Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 1519-1528.	27.0	984
381	Postoperative complications following colectomy for ulcerative colitis: A validation study. <i>BMC Gastroenterology</i> , 2012, 12, 39.	2.0	56
382	Decreasing Colectomy Rates for Ulcerative Colitis: A Population-Based Time Trend Study. <i>American Journal of Gastroenterology</i> , 2012, 107, 1879-1887.	0.4	174
383	Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. <i>American Journal of Gastroenterology</i> , 2012, 107, 1770-1776.	0.4	93
384	Implementing changes in clinical practice to improve the management of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S235-S242.	1.3	23
385	Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. <i>Gastroenterology</i> , 2012, 142, 46-54.e42.	1.3	4,013
386	Abatacept for Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 143, 62-69.e4.	1.3	127
387	Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease. <i>Gastroenterology</i> , 2012, 143, e26.	1.3	77
388	Anaerostipes hadrus comb. nov., a dominant species within the human colonic microbiota; reclassification of Eubacterium hadrum Moore et al. 1976. <i>Anaerobe</i> , 2012, 18, 523-529.	2.1	78
389	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 116-131.	1.3	18
390	Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 248-258.	1.3	38
391	Tu1306 Surgical Rates Have Decreased for Emergent Crohn's Disease Resections While Increasing for Elective Resections: A Population-Based Time Trend Study. <i>Gastroenterology</i> , 2012, 142, S-798.	1.3	1
392	Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. <i>American Journal of Gastroenterology</i> , 2012, 107, 179-194.	0.4	142
393	Deep Remission: A New Concept?. <i>Digestive Diseases</i> , 2012, 30, 107-111.	1.9	47
394	Up-Regulation of Annexin-A1 and Lipoxin A4 in Individuals with Ulcerative Colitis May Promote Mucosal Homeostasis. <i>PLoS ONE</i> , 2012, 7, e39244.	2.5	80
395	Development and Validation of an Administrative Case Definition for Inflammatory Bowel Diseases. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 711-717.	1.7	82
396	Inflammatory Bowel Disease: A Canadian Burden of Illness Review. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 811-817.	1.7	229

#	ARTICLE	IF	CITATIONS
397	Antibodies to mutated citrullinated vimentin and anti-cyclic citrullinated peptide antibodies in inflammatory bowel disease and related arthritis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1655-1662.	1.9	7
398	Assessment of Variables Associated with Smoking Cessation in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2012, 57, 1026-1032.	2.3	17
399	Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 152-160.	1.9	63
400	Biologic Treatment of Crohn's Disease: Adalimumab. , 2012, , 397-405.		0
401	Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2012, 107, S652.	0.4	0
402	Postoperative Complications and Mortality Following Colectomy for Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 972-980.	4.4	154
403	Long-Term Complications Responsible for Hospital Readmission Following a Colectomy for Ulcerative Colitis: A Population-Based Analysis. <i>Gastroenterology</i> , 2011, 140, S-770.	1.3	2
404	Economic Impact of Deep Remission in Adalimumab-Treated Patients With Crohn's Disease: Results From Extend. <i>Gastroenterology</i> , 2011, 140, S-205.	1.3	3
405	Identification of Subgroups of Adalimumab-Treated Patients With Crohn's Disease Who Experience High Rates of Deep Remission. <i>Gastroenterology</i> , 2011, 140, S-214.	1.3	2
406	A practical, evidence-based guide to the use of adalimumab in Crohn's disease. <i>Current Medical Research and Opinion</i> , 2011, 27, 1803-1813.	1.9	9
407	The in-Vitro Effect of Cigarette Smoke Extract on Monocyte-Derived Dendritic Cell Phenotypes is Different in Crohn's Disease Compared With Ulcerative Colitis Patients. <i>Gastroenterology</i> , 2011, 140, S-495.	1.3	0
408	Optimal C-Reactive Protein Cutoff Point for Predicting Hospitalization in Patients With Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2011, 140, S-421.	1.3	0
409	Venous Thromboembolism in the Hospitalized Ulcerative Colitis Patient. <i>Gastroenterology</i> , 2011, 140, S-428.	1.3	1
410	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	12.1	750
411	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose, and How to Predict Response?. <i>American Journal of Gastroenterology</i> , 2011, 106, 199-212.	0.4	356
412	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients with Moderately to Severely Active Crohn's Disease: Results through Week 36 from the CERTIFI Trial: 2011 ACG Presidential Poster. <i>American Journal of Gastroenterology</i> , 2011, 106, S463.	0.4	3
413	Safety of adalimumab in global clinical trials of patients with Crohn's disease.. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S43-S43.	1.9	0
414	PYRAMID Registry. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S44-S45.	1.9	2

#	ARTICLE	IF	CITATIONS
415	Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 565-569.	1.7	4
416	Efficacy and Safety of Adalimumab in Canadian Patients with Moderate to Severe Crohn's Disease: Results of the Adalimumab in Canadian Subjects with Moderate to Severe Crohn's Disease (ACCESS) Trial. Canadian Journal of Gastroenterology & Hepatology, 2011, 25, 419-425.	1.7	70
417	Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase 2b study of Ustekinumab in patients with moderately to severely active Crohn's disease. Inflammatory Bowel Diseases, 2011, 17, S24.	1.9	2
418	Exploring the role of monitoring anti-TNF drug and antibody levels in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2011, 4, 145-151.	3.2	5
419	PYRAMID registry: An observational study of adalimumab in Crohn's disease: results at year 3. Inflammatory Bowel Diseases, 2011, 17, S21.	1.9	3
420	Review article: defining remission in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2011, 34, 113-124.	3.7	180
421	Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2011, 34, 306-317.	3.7	39
422	Liver diseases associated with anti-tumor necrosis factor-alpha (TNF- α) use for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 479-484.	1.9	36
423	Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflammatory Bowel Diseases, 2011, 17, 1792-1799.	1.9	84
424	Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with IBD status of the host. Inflammatory Bowel Diseases, 2011, 17, 1971-1978.	1.9	437
425	Risk of Comorbidities on Postoperative Outcomes in Patients With Inflammatory Bowel Disease. Archives of Surgery, 2011, 146, 959.	2.2	66
426	Effect of Rural Living on the Development of the Inflammatory Bowel Diseases: A Nested Case-control Study. American Journal of Gastroenterology, 2011, 106, S474-S475.	0.4	1
427	Clostridium difficile Infection in Ulcerative Colitis: Increased Risk of Colectomy and Postoperative Infectious Complications. American Journal of Gastroenterology, 2011, 106, S481-S482.	0.4	0
428	Risk-benefit Assessment of Adalimumab and Certolizumab Pegol as Induction Treatment for Crohn's Disease. American Journal of Gastroenterology, 2011, 106, S466.	0.4	0
429	PYRAMID Registry: An Observational Study of Adalimumab in Crohn's Disease: Results at Year 3. American Journal of Gastroenterology, 2011, 106, S437-S438.	0.4	0
430	The Impact of Ulcerative Colitis on Patients' Lives Compared to Other Chronic Diseases: A Patient Survey. Digestive Diseases and Sciences, 2010, 55, 1044-1052.	2.3	57
431	Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2010, 31, 20-34.	3.7	96
432	Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2010, 31, 1296-1309.	3.7	88

#	ARTICLE	IF	CITATIONS
433	Accuracy of Administrative Data in Identifying Ulcerative Colitis Patients Presenting with Acute Flare and Undergoing Colectomy: 2010 Presidential Poster. American Journal of Gastroenterology, 2010, 105, S467.	0.4	1
434	Juvenile polyposis of the stomach—a novel cause of hypergastrinemia. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 583-588.	17.8	7
435	The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association. American Journal of Gastroenterology, 2010, 105, 2412-2419.	0.4	197
436	A pro-resolution mediator, prostaglandin D ₂ , is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12023-12027.	7.1	77
437	Review: Optimal use of biologics in the management of Crohn's disease. Therapeutic Advances in Gastroenterology, 2010, 3, 179-189.	3.2	36
438	Review: Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Therapeutic Advances in Gastroenterology, 2010, 3, 173-177.	3.2	25
439	Optimizing the safety of biologic therapy for IBD. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 93-101.	17.8	46
440	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. Medical Clinics of North America, 2010, 94, 1-18.	2.5	33
441	S1051 Methotrexate for the Prevention of Antibodies to Infliximab in Patients With Crohn's Disease. Gastroenterology, 2010, 138, S-167-S-168.	1.3	15
442	Influences of Intestinal Bacteria in Human Inflammatory Bowel Disease. Infectious Disease Clinics of North America, 2010, 24, 977-993.	5.1	34
443	Review: Anti-adhesion molecule therapy for inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2010, 3, 239-258.	3.2	97
444	Interferon- β 1a in Active Moderate to Severe Ulcerative Colitis: Efficacy and Safety from a Phase IIa Multicenter Study. American Journal of Gastroenterology, 2010, 105, S446.	0.4	2
445	Briakinumab (Anti-interleukin 12/23p40, ABT874) for Treatment of Crohn's Disease (CD). American Journal of Gastroenterology, 2010, 105, S457-S458.	0.4	8
446	The Incidence of Inflammatory Bowel Disease Across Time and Geography: A Systematic Review. American Journal of Gastroenterology, 2010, 105, S464-S465.	0.4	0
447	PYRAMID Registry: Observational Study of Adalimumab in Crohn's Disease at Year 2. American Journal of Gastroenterology, 2010, 105, S431.	0.4	0
448	Safety of Adalimumab in Global Clinical Trials of Patients with Crohn's Disease. American Journal of Gastroenterology, 2010, 105, S413-S414.	0.4	0
449	Quality-of-Life and Work Productivity Outcomes with Adalimumab for Patients Previously Treated with High-Dose Infliximab for Crohn's Disease. American Journal of Gastroenterology, 2010, 105, S435-S436.	0.4	0
450	Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut, 2009, 58, 940-948.	12.1	310

#	ARTICLE	IF	CITATIONS
451	Isotretinoin and intestinal inflammation: what gastroenterologists need to know. <i>Gut</i> , 2009, 58, 737-741.	12.1	34
452	Effect of ambient air pollution on the incidence of appendicitis. <i>Cmaj</i> , 2009, 181, 591-597.	2.0	108
453	Granulocyteâ€“monocyte apheresis for the treatment of ulcerative colitisâ€“is this the end of the road?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009, 6, 6-7.	1.7	6
454	Biological therapy in Crohn's disease: Is it an issue of how hard you strike or how fast you strike?. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 311-312.	1.9	0
455	Impact of ulcerative colitis from patients' and physicians' perspectives. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 581-588.	1.9	87
456	Inflammatory bowel disease patients who leave hospital against medical advice: Predictors and temporal trends. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 845-851.	1.9	29
457	Adalimumab safety in global clinical trials of patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1308-1319.	1.9	110
458	Managing the risks of IBD therapy. <i>Current Gastroenterology Reports</i> , 2009, 11, 509-517.	2.5	6
459	Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 977-986.	3.7	47
460	Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1863-1869.	0.9	175
461	700 Protease-Activated Receptor-4 (PAR4) Activation: Evidences for Its Role and Activation in the Pathogenesis of Colitis and in Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2009, 136, A-110.	1.3	1
462	P008 - Adalimumab sustains quality-of-life improvements in patients with Crohn's disease: 3-year data from CHARM. <i>Journal of Crohn's and Colitis</i> , 2009, 3, S14.	1.3	4
463	P205 - Outcome of patients with Crohn's disease and primary sclerosing cholangitis in CHARM and GAIN. <i>Journal of Crohn's and Colitis</i> , 2009, 3, S91-S92.	1.3	1
464	Evidence of Endothelial Dysfunction in Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 175-182.	4.4	98
465	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 577-594.	2.2	22
466	Adalimumab Therapy maintains meaningful rates of steroid-free remission in patients with Crohn's Disease for up to 3 Years of Therapy: Results From an Open-Label Extension of CHARM. <i>Inflammatory Bowel Diseases</i> , 2009, 15, S41-S42.	1.9	0
467	TOUCHâ„¢ Study Patient Outcomes: The Impact of Natalizumab on Common Measures of Quality of Life in CD patients. <i>American Journal of Gastroenterology</i> , 2009, 104, S418.	0.4	0
468	TOUCHâ„¢ Study Patient Outcomes: The Impact of Natalizumab on Crohn's Disease Severity. <i>American Journal of Gastroenterology</i> , 2009, 104, S420.	0.4	0

#	ARTICLE	IF	CITATIONS
469	TOUCHâ„¢ Study Patient Outcomes: The Impact of Natalizumab on Utilization of Healthcare Resources by the Patients and Their Associated Treatment Satisfaction. <i>American Journal of Gastroenterology</i> , 2009, 104, S416.	0.4	0
470	Results from an Observational Study of Adalimumab in Crohn's Disease: The PYRAMID Registry. <i>American Journal of Gastroenterology</i> , 2009, 104, S462-S463.	0.4	0
471	TOUCHâ„¢ Study Patient Outcomes: Workforce Participation, Productivity and the Impact of Natalizumab. <i>American Journal of Gastroenterology</i> , 2009, 104, S417-S418.	0.4	0
472	Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1455-1461.	2.3	41
473	Are physicians biased in their choices of therapy to recommend to patients with IBD?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S204-S205.	1.9	1
474	Use of combination therapy in IBD. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S219-S221.	1.9	2
475	I am Jewish: What is my risk of developing Crohn's disease?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S26-S27.	1.9	2
476	Medical induction of active Crohn's ileitis: Evidence-based management. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S247-S248.	1.9	0
477	Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 674-688.	3.7	84
478	A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease. <i>Gastroenterology</i> , 2008, 135, 294-295.	1.3	58
479	Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study. <i>Gastroenterology</i> , 2008, 135, 1493-1499.	1.3	339
480	Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 1218-1224.	4.4	372
481	Microscopic Colitisâ€”Defining Incidence Rates and Risk Factors: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 35-40.	4.4	129
482	Adalimumab for the treatment of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1011-1019.	3.1	8
483	Anti-Adhesion Molecule Strategies for Crohn Disease. <i>BioDrugs</i> , 2008, 22, 259-264.	4.6	14
484	Hepatosplenic T cell lymphoma in inflammatory bowel disease. <i>Gut</i> , 2008, 57, 1639-1641.	12.1	137
485	Review: Efficacy and safety of adalimumab in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2008, 1, 43-50.	3.2	26
486	Ulcerative colitis: patients' perceptions compared with other chronic diseases. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S22.	1.9	0

#	ARTICLE	IF	CITATIONS
487	Quality of life improvements with Natalizumab maintenance therapy in patients exposed to or failing TNF-alpha inhibitor therapy in the ENACT-2 Trial. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S25.	1.9	0
488	Living with ulcerative colitis: differing perceptions of patients and gastroenterologists. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S22-S23.	1.9	0
489	Impact of Adalimumab therapy after 12 Weeks in patients with Crohn's Disease who were nonresponders at week 4. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S28.	1.9	0
490	Adalimumab maintains long-term remission through 2 years in patients with moderate to severe Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S36-S37.	1.9	0
491	Quality of life improvements with Natalizumab induction therapy in patients exposed to or failing TNF-alpha inhibitor therapy in the ENCORE Trial. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S28-S29.	1.9	0
492	Steroid-Free remission in response to Adalimumab therapy over 2 years in patients with Crohn's Disease: Results From open-label extension of the CHARM trial. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S33.	1.9	0
493	Medical induction of active Crohn's ileitis. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S247-S248.	1.9	0
494	Biologic therapy in Crohn's disease: state of the art. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 475-481.	2.3	6
495	Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2008, 22, 261-272.	1.7	10
496	Response after 12 Weeks of Adalimumab Therapy in Patients with Crohn's Disease Who Were Nonresponders at Week 4. <i>American Journal of Gastroenterology</i> , 2008, 103, S379.	0.4	5
497	Does Multi-Drug Crohn's Therapy Result in Improved Patient Outcomes?. <i>American Journal of Gastroenterology</i> , 2008, 103, S403.	0.4	0
498	Long-Term Adalimumab Treatment Is Associated with Sustained Fistula Healing in Patients with Moderate to Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, S417.	0.4	1
499	The Access Trial. <i>American Journal of Gastroenterology</i> , 2008, 103, S382.	0.4	0
500	Air Pollution and Appendicitis. <i>American Journal of Gastroenterology</i> , 2008, 103, S113.	0.4	0
501	IBD Patients Who Leave Against Medical Advice. <i>American Journal of Gastroenterology</i> , 2008, 103, S419.	0.4	0
502	Short-and Long-Term Efficacy of Adalimumab Following Infliximab Failure. <i>American Journal of Gastroenterology</i> , 2008, 103, S450.	0.4	0
503	Predicting Postoperative Mortality from Comorbidity Indices in Administrative Databases Among Inflammatory Bowel Disease Patients. <i>American Journal of Gastroenterology</i> , 2008, 103, S446-S447.	0.4	1
504	Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. <i>Gut</i> , 2007, 56, 1232-1239.	12.1	866

#	ARTICLE	IF	CITATIONS
505	Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. <i>Annals of Internal Medicine</i> , 2007, 146, 829.	3.9	849
506	Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial. <i>Gastroenterology</i> , 2007, 132, 52-65.	1.3	1,986
507	Natalizumab for the Treatment of Active Crohn's Disease: Results of the ENCORE Trial. <i>Gastroenterology</i> , 2007, 132, 1672-1683.	1.3	586
508	Refractory Crohn's Disease of the Vulva Treated with Infliximab: A Case Report. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 835-837.	1.7	21
509	Adalimumab Safety in Crohn's Disease Patients: Open-Label Maintenance Following the Gain and CHARM Trials. <i>American Journal of Gastroenterology</i> , 2007, 102, S496-S497.	0.4	3
510	Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1401-1407.	1.9	31
511	Once- or Twice-Daily MMX, Mesalamine for the Maintenance of Remission of Mild or Moderate Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, S463.	0.4	1
512	The Effect of Prolonged Therapy with MMX, Mesalamine in Patients with Acute, Mild-to-Moderate Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, S463.	0.4	1
513	The Impact of Ulcerative Colitis on Patients' Lives Compared with Other Chronic Diseases: A Patient Survey. <i>American Journal of Gastroenterology</i> , 2007, 102, S482.	0.4	0
514	Natalizumab Does Not Require the Concomitant Use of Immunosuppressants or Corticosteroids for the Induction of Sustained Response and Remission in Patients with Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2007, 102, S494.	0.4	0
515	Item Content Validation for Two New Measures To Assess Crohn's Disease Patients' Interest in Medication Change. <i>American Journal of Gastroenterology</i> , 2007, 102, S492.	0.4	0
516	Natalizumab Induces Sustained Response and Remission in the Absence of Concomitant Immunosuppressants in Patients with Crohn's Disease Who Failed Prior Anti-TNF Therapy. <i>American Journal of Gastroenterology</i> , 2007, 102, S493.	0.4	0
517	Exposing the Weaknesses: A Systematic Review of Azathioprine Efficacy in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2007, 102, S460.	0.4	0
518	Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn's Disease: the CLASSIC-I Trial. <i>Gastroenterology</i> , 2006, 130, 323-333.	1.3	1,523
519	The Approach to Dysplasia Surveillance in Inflammatory Bowel Disease. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 251-253.	1.7	5
520	Multimodal Immunosuppressant Therapy in Steroid-Refractory Common Variable Immunodeficiency Sprue: A Case Report Complicating Cytomegalovirus Infection. <i>International Journal of Surgical Pathology</i> , 2006, 14, 101-106.	0.8	13
521	Adalimumab Rapidly Induces Clinical Remission and Response in Patients with Moderate to Severe Crohn's Disease Who Had Secondary Failure to Infliximab Therapy. <i>American Journal of Gastroenterology</i> , 2006, 101, S448.	0.4	18
522	Natalizumab Maintains Remission for 2 Years in Patients with Moderately to Severely Active Crohn's Disease and in Those with Prior Infliximab Exposure. <i>American Journal of Gastroenterology</i> , 2006, 101, S450.	0.4	3

#	ARTICLE	IF	CITATIONS
523	Adalimumab Maintains Clinical Remission and Response in Patients with Active Crohn's Disease. American Journal of Gastroenterology, 2006, 101, S458.	0.4	1
524	Hematopoietic cell transplantation for Crohn's disease; is it time?. World Journal of Gastroenterology, 2006, 12, 6665.	3.3	37
525	Adalimumab Safety in Crohn's Disease and Rheumatoid Arthritis Clinical Trials, Reduced Mortality in Rheumatoid Arthritis. American Journal of Gastroenterology, 2006, 101, S452-S453.	0.4	0
526	Immunogenicity of Natalizumab in Crohn's Disease Following Continuous or Interrupted Dosing. American Journal of Gastroenterology, 2006, 101, S446.	0.4	0
527	Methotrexate: Lessons from Rheumatology. Canadian Journal of Gastroenterology & Hepatology, 2005, 19, 541-542.	1.7	4
528	Natalizumab Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine, 2005, 353, 1912-1925.	27.0	880
529	Advances in medical therapy of inflammatory bowel disease. Current Opinion in Pharmacology, 2005, 5, 566-72.	3.5	23
530	Inappropriate Use of Intravenous Pantoprazole: Extent of the Problem and Successful Solutions. Clinical Gastroenterology and Hepatology, 2005, 3, 1207-1214.	4.4	35
531	Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohn's Disease Patients. American Journal of Gastroenterology, 2005, 100, S310-S311.	0.4	2
532	Maintenance of Remission over 1 Year in Patients with Active Crohn's Disease Treated with Adalimumab. American Journal of Gastroenterology, 2005, 100, S311.	0.4	5
533	Rapid Response to Human Anti-TNF Monoclonal Antibody Adalimumab in Patients with Moderate to Severely Active Crohn's Disease in the CLASSIC Study. American Journal of Gastroenterology, 2005, 100, S313-S314.	0.4	1
534	Remission and Clinical Response Induced and Maintained in Patients with Active Crohn's Disease Treated for 1-Year Open-Label with Adalimumab. American Journal of Gastroenterology, 2005, 100, S316-S317.	0.4	2
535	Screening for Dysplasia in Primary Sclerosing Cholangitis - A Population-Based Assessment of Physician Practices. American Journal of Gastroenterology, 2005, 100, S314.	0.4	0
536	The Ultimate Therapeutic Goal: Establishing and Maintaining Quality of Life. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 465-466.	1.7	0
537	Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease. Canadian Journal of Gastroenterology & Hepatology, 2004, 18, 503-508.	1.7	25
538	Isolated Visceral Small Artery Fibromuscular Hyperplasia-Induced Ischemic Colitis Mimicking Inflammatory Bowel Disease. American Journal of Gastroenterology, 2004, 99, 2058-2062.	0.4	19
539	The Race to Block TNF: The Caution Flag Is Raised Again. Inflammatory Bowel Diseases, 2004, 10, 61-62.	1.9	0
540	Autoimmune Disorders and Extraintestinal Manifestations in First-degree Familial and Sporadic Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 207-214.	1.9	132

#	ARTICLE	IF	CITATIONS
541	A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). <i>Gastroenterology</i> , 2004, 127, 332.	1.3	19
542	Medical therapy of Crohn disease. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 351-359.	2.3	2
543	ADALIMUMAB, A HUMAN ANTI-TNF- α MONOCLONAL ANTIBODY, INDUCES CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE CROHN'S DISEASE IRRESPECTIVE OF SMOKING STATUS. <i>American Journal of Gastroenterology</i> , 2004, 99, S259-S260.	0.4	2
544	ENACT-2 SAFETY, TOLERABILITY, AND IMMUNOGENICITY RESULTS OF NATALIZUMAB IN PATIENTS WITH CROHN'S DISEASE. <i>American Journal of Gastroenterology</i> , 2004, 99, S269.	0.4	0
545	EFFICACY ASSESSMENT OF NATALIZUMAB IN PATIENTS WITH CROHN'S DISEASE AND PRIOR HISTORY OF INFLIXIMAB THERAPY. <i>American Journal of Gastroenterology</i> , 2004, 99, S270.	0.4	0
546	EFFICACY, SAFETY, AND TOLERABILITY OF NATALIZUMAB IN MAINTAINING CLINICAL RESPONSE AND REMISSION IN CROHN'S DISEASE (ENACT-2). <i>American Journal of Gastroenterology</i> , 2004, 99, S255-S256.	0.4	0
547	Combined Seton Placement, Infliximab Infusion, and Maintenance Immunosuppressives Improve Healing Rate in Fistulizing Anorectal Crohn's Disease. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 577-583.	1.3	227
548	The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. <i>Gastroenterology</i> , 2002, 122, 875-880.	1.3	984
549	Giant Cell Myocarditis in a Patient With Crohn's Disease, Treated with Etanercept – A Tumour Necrosis Factor-Alpha Antagonist. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2001, 15, 607-611.	1.7	30
550	Infliximab for the Treatment of Crohn'S Disease: Review and Indications for Clinical Use in Canada. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2001, 15, 371-375.	1.7	15
551	Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. <i>American Journal of Gastroenterology</i> , 2001, 96, 722-729.	0.4	292
552	Prevalence of extraintestinal manifestations and autoimmune disorders in patients with familial and sporadic inflammatory bowel disease. <i>Gastroenterology</i> , 2000, 118, A336.	1.3	0
553	Infliximab for Crohn's disease in clinical practice at the Mayo clinic: The first 100 patients. <i>Gastroenterology</i> , 2000, 118, A568.	1.3	15
554	Health-related quality of life in Crohn's disease: Whose preferences should we use?. <i>Gastroenterology</i> , 2000, 118, A214.	1.3	0
555	Is antibody testing for inflammatory bowel disease clinically useful?. <i>Gastroenterology</i> , 1999, 116, 1001-1002.	1.3	36
556	Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: a cost minimization analysis. <i>Gastrointestinal Endoscopy</i> , 1999, 50, 492-498.	1.0	64
557	Successful management of Crohn's disease of the ileoanal pouch with infliximab. <i>Gastroenterology</i> , 1999, 117, 429-432.	1.3	138
558	Physicians' perception of utility in Crohn's disease. <i>Gastroenterology</i> , 1998, 114, A1047.	1.3	0